Jacek Kubica
Cardiology — Nicolaus Copernicus University, Poland
Jacek Kubica
LeadR Profile
Cardiology
Subspecialties: Internal Medicine - Biochemistry - Public Health
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 447
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Dual antithrombotic therapy with dabigatran and ticagrelor in patients with acute coronary syndrome and non-valvular atrial fibrillation undergoing percutaneous coronary intervention (ADONIS-PCI): protocol for a randomized controlled pilot trial. stents, pilots, embolism, hemorrhage, stroke, ticagrelor, cardiovascular diseases, percutaneous coronary intervention, acute coronary syndrome, aspirin, atrial fibrillation, cardiology, coronary artery bypass, therapeutics, dabigatran | Cardiol J | 2026 | 0 |
| Beyond the Four Pillars: A Risk-Targeted Framework for Vericiguat-A Narrative Review. safety, heart failure, heart, heart failure, systolic, therapeutics, soluble guanylyl cyclase | J Clin Med | 2026 | 0 |
| Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort Study. safety, hemorrhage, ischemic stroke, stroke, myocardial infarction, percutaneous coronary intervention, clopidogrel, cohort studies, aspirin, secondary prevention, therapeutics | JACC Asia | 2026 | 0 |
| Modulation of gut microFLORA with rifaximin to reduce high platelet reactivity in post-ACS patients on ticagrelor: rationale and design of the FLORA-ACS study. ticagrelor, cardiovascular diseases, cardiology, rifaximin, blood platelets, gastrointestinal microbiome | Cardiol J | 2026 | 0 |
| Primary Results of the SALAMANDER Registry: A Multicenter Observational Cohort Study. registries, anticoagulants, heart diseases, safety, hemorrhage, cohort studies, therapeutics, direct-acting oral anticoagulants | J Am Heart Assoc | 2026 | 0 |
Clinical Studies 32
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment NCT05905965 — waist-hip ratio, therapeutics, metabolic syndrome | Phase 3 | Recruiting | 2023 |
| Evaluation of Safety and Efficacy of Two Ticagrelor based De escalation Antiplatelet Strategies in Acute Coronary Syndrome NCT04718025 — safety, ticagrelor, acute coronary syndrome, aspirin, st elevation myocardial infarction, therapeutics, non-st elevated myocardial infarction, angina, unstable | Phase 3 | Recruiting | 2022 |
LeadR Networks
Main global connection map